Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALVRNASDAQ:FGENNASDAQ:PIRSNASDAQ:PWUP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALVRAlloVir$7.40-8.3%$9.72$7.96▼$24.15$37.32M0.6316,112 shs16,077 shsFGENFibroGen$0.29-2.8%$0.44$0.18▼$1.82$28.66M0.822.29 million shs1.19 million shsPIRSPieris Pharmaceuticals$13.60-15.7%$15.17$6.20▼$18.68$17.95M0.6159,985 shs51,700 shsPWUPPowerUp Acquisition$0.58-0.8%$5.15$8.05▼$15.80$4.49M0.0512,013 shs154,589 shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALVRAlloVir+0.88%-12.38%-17.57%-22.73%-54.29%FGENFibroGen-3.89%-10.27%-18.34%-46.08%-79.98%PIRSPieris Pharmaceuticals0.00%0.00%0.00%0.00%-1.33%PWUPPowerUp Acquisition0.00%-9.66%-42.75%-94.93%-94.77%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALVRAlloVir1.8802 of 5 stars0.05.00.00.01.34.20.6FGENFibroGen4.3668 of 5 stars3.34.00.04.72.33.30.6PIRSPieris PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/APWUPPowerUp AcquisitionN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALVRAlloVir 0.00N/AN/AN/AFGENFibroGen 2.50Moderate Buy$10.003,396.50% UpsidePIRSPieris Pharmaceuticals 0.00N/AN/AN/APWUPPowerUp Acquisition 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest PIRS, FGEN, PWUP, and ALVR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/1/2025FGENFibroGenWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform3/18/2025FGENFibroGenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.002/20/2025FGENFibroGenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00(Data available from 4/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALVRAlloVirN/AN/AN/AN/A$29.35 per shareN/AFGENFibroGen$29.62M0.97N/AN/A($1.87) per share-0.15PIRSPieris Pharmaceuticals$42.81M0.42N/AN/A$21.66 per share0.63PWUPPowerUp AcquisitionN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALVRAlloVir-$190.42M-$20.23N/A∞N/AN/A-71.03%-61.27%5/12/2025 (Estimated)FGENFibroGen-$284.23M-$0.48N/AN/AN/A-67.66%N/A-36.17%5/5/2025 (Estimated)PIRSPieris Pharmaceuticals-$24.54M-$12.10N/A∞N/A-39.71%-80.93%-59.55%N/APWUPPowerUp AcquisitionN/AN/A0.00∞N/AN/AN/AN/AN/ALatest PIRS, FGEN, PWUP, and ALVR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/17/2025Q4 2024FGENFibroGen-$0.08-$0.08N/A$0.18$24.91 million$3.14 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALVRAlloVirN/AN/AN/AN/AN/AFGENFibroGenN/AN/AN/AN/AN/APIRSPieris PharmaceuticalsN/AN/AN/AN/AN/APWUPPowerUp AcquisitionN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALVRAlloVirN/A86.7886.78FGENFibroGenN/A1.281.16PIRSPieris PharmaceuticalsN/A4.824.82PWUPPowerUp AcquisitionN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALVRAlloVir66.05%FGENFibroGen72.71%PIRSPieris Pharmaceuticals40.11%PWUPPowerUp Acquisition19.17%Insider OwnershipCompanyInsider OwnershipALVRAlloVir32.07%FGENFibroGen1.98%PIRSPieris Pharmaceuticals6.39%PWUPPowerUp Acquisition48.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALVRAlloVir1105.04 million3.43 millionOptionableFGENFibroGen570100.92 million98.78 millionOptionablePIRSPieris Pharmaceuticals1401.32 million1.24 millionOptionablePWUPPowerUp AcquisitionN/A7.77 million4.04 millionNot OptionablePIRS, FGEN, PWUP, and ALVR HeadlinesRecent News About These CompaniesReviewing PowerUp Acquisition (NASDAQ:PWUP) and Innventure (NASDAQ:INV)March 29, 2025 | americanbankingnews.comAspire Biopharma, Inc.: Aspire Biopharma Holdings, Inc., Announces Public Listing on NasdaqFebruary 20, 2025 | finanznachrichten.deAspire Biopharma, PowerUp Acquisition complete business combinationFebruary 20, 2025 | markets.businessinsider.comAspire Biopharma announces public listing on NasdaqFebruary 20, 2025 | markets.businessinsider.comAspire Biopharma Holdings, Inc., Announces Public Listing on NasdaqFebruary 20, 2025 | accessnewswire.comAspire Biopharma Holdings, Inc., Announces Public Listing on NasdaqFebruary 19, 2025 | accessnewswire.com(PWUP) Technical Pivots with Risk ControlsFebruary 13, 2025 | news.stocktradersdaily.comPowerUp Acquisition Corp trading resumesFebruary 12, 2025 | markets.businessinsider.comPowerUp Acquisition Corp trading halted, volatility trading pauseFebruary 12, 2025 | markets.businessinsider.comPowerUp Stock Soars to All-Time High of $14.84 Amidst Strong GrowthFebruary 11, 2025 | msn.comPowerUp Acquisition Corp. Approves Merger with Aspire BiopharmaFebruary 11, 2025 | msn.comWhen (PWUP) Moves Investors should ListenFebruary 2, 2025 | news.stocktradersdaily.comPowerUp Acquisition Corp. Cl AJanuary 17, 2025 | wsj.comHow to Take Advantage of moves in (PWUP)January 12, 2025 | news.stocktradersdaily.comPWUP PowerUp Acquisition Corp.December 12, 2024 | seekingalpha.comHow To Trade (PWUP)November 19, 2024 | news.stocktradersdaily.comWhen the Price of (PWUP) Talks, People ListenOctober 18, 2024 | news.stocktradersdaily.comSHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Mergers of PWUP and ESGROctober 9, 2024 | prnewswire.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates K, PWUP, RVNC, ESGR on Behalf of ShareholdersOctober 8, 2024 | stockhouse.comSHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Mergers of PWUP, ESGROctober 7, 2024 | accesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePIRS, FGEN, PWUP, and ALVR Company DescriptionsAlloVir NASDAQ:ALVR$7.40 -0.67 (-8.30%) As of 04/3/2025AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.FibroGen NASDAQ:FGEN$0.29 -0.01 (-2.82%) As of 12:47 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.Pieris Pharmaceuticals NASDAQ:PIRSPieris Pharmaceuticals, Inc., a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc.; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies. The company was founded in 2001 and is headquartered in Boston, Massachusetts.PowerUp Acquisition NASDAQ:PWUP$0.58 0.00 (-0.76%) As of 04/1/2025PowerUp Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It intends to focus on video gaming, gaming adjacent, and metaverse businesses. PowerUp Acquisition Corp. was incorporated in 2021 and is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Ecosystem Edge: Joby's Competitive Advantage Intel’s Big Bet on 18A: Will Lip-Bu Tan’s Vision Pay Off? Lamb Weston Stock Rises, Earnings Provide Calm Amidst Chaos Sportsman’s Warehouse Trading Volume Spike Signals Opportunity Broadcom’s VMware Strategy Could Fuel the Next AVGO Rally Arm Holdings Aims for 50% Data Center Market Share Cathie Wood Loads Up on Baidu—Is It the Right Time to Buy? Celsius Heats Up: Acquisition, Analyst Upgrade Fuel Momentum Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
